Houston、TXにおけるリンパ腫の臨床試験
Houstonとその周辺地域（約30マイル以内）の拠点で、リンパ腫に関する34件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
被験者募集中第1相
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
被験者募集中観察研究
- Texas Children's Hospital, Houston
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
被験者募集中第1相
- The University of Texas - MD Anderson Cancer Center, Houston
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
被験者募集中第2相
- MD Anderson Cancer Center, Houston
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
被験者募集中第1/2相
- Baylor College of Medicine, Houston
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
被験者募集中第1相
- University of Texas - MD Anderson Cancer Center, Houston
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
被験者募集中第1/2相
- Research Site, Houston
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
被験者募集中第1/2相
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
被験者募集中第3相
- Research Site, Houston
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
被験者募集中第1相
- Baylor College of Medicine, Houston
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
被験者募集中第1相
- The University of Texas MD Anderson Cancer Center, Houston
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
被験者募集中第1/2相
- MD Anderson, Houston
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
被験者募集中第1/2相
- MD Anderson Cancer Center, Houston
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
被験者募集中第2相
- MD Anderson Cancer Center, Houston
Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma
被験者募集中第1相
- UT MD Anderson, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
被験者募集中第1/2相
- University of Texas MD Anderson Cancer Center, Houston
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
被験者募集中第3相
- MD Anderson Cancer Center, Houston
A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
被験者募集中第1相
- The University of Texas M D Anderson Cancer Center, Houston
A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
被験者募集中第2相
- MD Anderson Cancer Center, Houston
A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma
被験者募集中第2相
- MD Anderson Cancer Center, Houston
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
被験者募集中第2相
- MD Anderson Cancer Center, Houston
DALY II USA/ MB-CART2019.1 for DLBCL
被験者募集中第2相
- The University of Texas MD Anderson Cancer Center, Houston
A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)
被験者募集中第1相
- MD Anderson, Houston
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
被験者募集中第1相
- MD Anderson Cancer Center, Houston
CD4CAR for CD4+ Leukemia and Lymphoma
被験者募集中第1相
- The University of Texas MD Anderson Cancer Center, Houston
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
被験者募集中第1/2相
- Dren Investigational Site, Houston
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
被験者募集中観察研究
- M D Anderson Cancer Center, Houston
Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas
被験者募集中
- MD Anderson Cancer Center, Houston
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
被験者募集中観察研究
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
被験者募集中第1/2相
- The University of Texas MD Anderson Cancer Center, Houston
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
被験者募集中第1相
- MD Anderson Cancer Center, Houston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
被験者募集中第2相
- MD Anderson, Houston
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
被験者募集中第1相
- Harris Health System (includes ben Taub General Hospital and Smith), Houston
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
被験者募集中第1相
- The University of Texas MD Anderson Cancer Center, Houston
他の都市におけるリンパ腫の試験
- Boston, MA33件の研究
- New York City, NY33件の研究
- Washington, DC23件の研究
- Baldwin Park, CA21件の研究
- Chicago, IL20件の研究
- Durham, NC17件の研究
- St. Louis, MO15件の研究
- Philadelphia, PA15件の研究
- Cleveland, OH14件の研究
- Edison, NJ12件の研究
- Atlanta, GA12件の研究
- Seattle, WA12件の研究
Houstonにおける他の研究
- 非小細胞肺癌145件の研究
- 乳がん126件の研究
- がん（全種類）121件の研究
- 転移性癌104件の研究
- 大腸癌102件の研究
- 卵巣がん89件の研究
- 急性骨髄性白血病85件の研究
- 肺がん78件の研究
- 前立腺がん76件の研究
- 子宮内膜がん68件の研究
- 膵臓がん61件の研究
- 悪性黒色腫59件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。